Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
NCT03897309
Completed
VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 with Monovalent or Bivalent Dosing in Healthy Adult Volunteers. The study consists of 2 parts: Part 1 is the double-blinded portion where subjects will be randomized to one of two monovalent vaccine groups, bivalent vaccine group or placebo. Subjects will be followed for \~4 weeks post vaccination for... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
09/19/2022
Locations: Rapid Medical Research, Cleveland, Ohio
Conditions: Norovirus Infection
Register for Updates
Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults
NCT02654080
Completed
The purpose of this study is to evaluate the safety and tolerability of an HIV-1 nef/tat/vif, env pDNA vaccine delivered with electroporation (EP), followed by a recombinant vesicular stomatitis virus (rVSV) HIV envC vaccine boost, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Case Clinical Research Site, Cleveland, Ohio +1 locations
Conditions: HIV Infections
Register for Updates
Flu Vaccine Study in Neuromuscular Patients 2011
NCT01422200
Completed
The purpose of the study is to compare the immune response of two different injection methods (Intramuscular V.S. Subcutaneous) of the 2011-2012 seasonal Influenza (Flu) vaccine among patients with neuromuscular conditions who have significant muscle degeneration. This research study hypothesizes that the subcutaneous route of vaccine administration, as compared to the intramuscular route, may confer at least comparable, or possibly better, immunogenicity. At least 30 individuals followed by the... Read More
Gender:
ALL
Ages:
Between 3 years and 35 years
Trial Updated:
10/14/2020
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Congenital Muscular Dystrophy
Register for Updates
A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
NCT03527173
Completed
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the GSK3536852A vaccine, which was designed to protect against shigellosis caused by Shigella sonnei (S. sonnei) and is using the new Generalized Modules for Membrane Antigens (GMMA) platform technology developed by GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH). The study vaccine could be the stepping stone for the development of a multivalent broadly protective Shigella vaccine for vaccinati... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/16/2020
Locations: GSK Investigational Site, Cincinnati, Ohio
Conditions: Dysentery, Bacillary
Register for Updates
Safety of Sublingual dmLT for ETEC
NCT02052934
Completed
A Phase 1 dose escalating study of ETEC candidate vaccine to determine safety and immunogenicity of a multi-dose regimen in healthy adult volunteers. The study will be conducted at Cincinnati Children's Hospital Medical Center (CCHMC). The primary objectives assess the safety and tolerability of dmLT vaccine when administered in three doses sublingually over a range of dosages in healthy adult subjects. The secondary objectives assess long-term safety follow-up from immunization through Month 7... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/24/2019
Locations: Cincinnati Children's Hospital Medical Center - Gastroenterology, Hepatology and Nutrition, Cincinnati, Ohio
Conditions: Gastroenteritis Escherichia Coli
Register for Updates
MUC1 Vaccine for Triple-negative Breast Cancer
NCT00986609
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. PURPOSE: To evaluate the efficacy of poly-ICLC + MUCI peptide vaccine in boosting the immunologic response to MUCI in patients with triple-negative BC
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/19/2018
Locations: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Register for Updates
High-Dose Influenza Vaccine in Nursing Homes
NCT01815268
Unknown
The purpose of this study is to prospectively evaluate relative effectiveness of high dose influenza vaccine in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the standard dose trivalent seasonal influenza vaccine.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/13/2018
Locations: Case Western Reserve University, Cleveland, Ohio +2 locations
Conditions: Influenza
Register for Updates
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
NCT02542462
Completed
This is a prospective randomized clinical trial that aims to evaluate the potential effects of the first dose of rotavirus vaccines on gastrointestinal motility and anatomy and blood and stool cytokine responses. It will also assess the association between these outcomes and the pattern of the shedding of vaccine strain rotavirus in the stool. Infants will be randomized to one of four arms: monovalent rotavirus vaccine (Rotarix®, RV1) alone, RV1 with other recommended vaccines, pentavalent rotav... Read More
Gender:
ALL
Ages:
Between 42 days and 90 days
Trial Updated:
07/11/2018
Locations: Cincinnati Children's Hosptital Medical Center, Cincinnati, Ohio
Conditions: Intussusception, Rotavirus Infections
Register for Updates
Pneumonia Vaccine in Aging HIV Positive Individuals
NCT02558751
Completed
The investigators hypothesized that vaccination with either the 23-valent pneumococcal polysaccharide vaccine (PPV23) alone or the 13-valent pneumococcal conjugate vaccine (PCV 13) followed by PPV23 results in similar antibody levels/functional activity and induce a similar pneumococcal polysaccharide (PPS)-specific B cell response in HIV-positive individuals \>50 years of age and HIV-negative persons\>50 years of age. The investigators immunized the study group HIV+ persons\>50 and controls (HI... Read More
Gender:
ALL
Ages:
Between 50 years and 65 years
Trial Updated:
09/23/2015
Locations: The University of Toledo-Health Science Campus, Toledo, Ohio
Conditions: Pneumococcal Infection
Register for Updates
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
NCT06908096
Not Yet Recruiting
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population. Mono can be serious, and it can lead to severe illnesses like cancer and autoimmune diseases. Researchers want to test vaccines that may help prevent EBV and associated diseases. Objective: To test two EBV vaccines: EBV gH/gL/gp42-ferritin and EBV gp350-ferritin. Eligibility: Healthy EBV-negative or EBV-positive people aged 18 to... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
04/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
Register for Updates
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/16/2025
Locations: Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013, Birmingham, Alabama +40 locations
Conditions: Pneumococcal Immunization
Register for Updates
A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Active Not Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Pinnacle Research Group, Anniston, Alabama +144 locations
Conditions: SARS-CoV2, COVID-19
Register for Updates